4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Breast: new trials by email Literature Review of Breast trials Research Report on Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer PLX038 - Breast, Cancer | Phase 2 | Terminated | Institut Curie | 14 | 2024-04-17 | 2026-01-02 |
| Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy Use of Bupivacaine in pectoral nerve block in mastectomy, use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy, Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy - Cancer, Breast | Phase 2 | Completed | Beni-Suef University | 72 | 2022-12-01 | 2024-12-27 |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine - Breast, Metastatic | Phase 1 / Phase 2 | Recruiting | University of Southern California | 65 | 2020-09-26 | 2026-03-10 |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Olaparib, MEDI4736, Bevacizumab - Ovarian, Breast | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 264 | 2016-03-17 | 2026-07-14 |
| Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats olaparib - Ovarian, Breast | Phase 2 | Completed | AstraZeneca | 298 | 2010-02-21 | 2025-08-13 |
| Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Pycnogenol - Lymphedema, Breast | Phase 2 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 26 | 2003-08-01 | 2008-04-22 |
| Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer Carboplatin, Capecitabine, Vinorelbine - Breast, Cancer | Phase 1 / Phase 2 | Completed | University of New Mexico | 33 | 2000-05-01 | 2010-01-07 |
Neoplasms (5) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Lymphedema (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adnexal Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
olaparib (2) · Bevacizumab (1) · Bupivacaine (1) · Capecitabine (1) · Carboplatin (1) · Ketamine (1) · Magnesium Sulfate (1) · Mastectomy (1) · Vinorelbine (1) · durvalumab (1) · pycnogenols (1) · sarilumab (1)
AstraZeneca (2) · Beni-Suef University (1) · Institut Curie (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · University of New Mexico (1) · University of Southern California (1)
United States (5) · France (2) · Israel (2) · Australia (1) · Egypt (1) · Germany (1) · Netherlands (1) · South Korea (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Anastasia Martynova, MD (1) · Bella Kaufman, MD (1) · Doaa M Khalil, lecturer (1) · Ian Rabinowitz, MD (1) · James F. Cleary, M.B.B.S. (1) · Jane Robertson, BSc, MBCHB, MD (1) · Susan Domchek, MD (1)
PMID 25376971, PMID 26723501, PMID 26961146, PMID 32771088, PMID 35756843, PMID 37939124
2015 (1), R01CA238387 (1)